Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease
Tweet Send to a Friend
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


